• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NICOTINE Drug Record

  • Summary
  • Interactions
  • Claims
  • NICOTINE chembl:CHEMBL3 Approved

    Alternate Names:

    NIQUITIN MINIS ORANGE
    NICABATE
    NIQUITIN
    STUBIT
    NICOTROL
    NICOTROL NS
    NICOTINELL TTS 30
    NICOPASS
    NICOTINE
    NICORETTE INVISI
    NICOTINELL SUPPORT
    NIQUITIN MINIS CHERRY
    NIQUITIN PRE-QUIT
    NICOPATCH
    NICOTINELL TTS 20
    NIQUITIN CLR
    STOPPERS
    NICOTINELL CLASSIC
    NIQUITIN MINIS MINT
    NICODERM CQ
    NICOTINELL TTS 10
    NICOTROL INHALER
    NIQUITIN MINT
    NIQUITIN STRIPS MINT
    PROSTEP
    HABITROL
    NICODERM

    Drug Info:

    Year of Approval 1996
    Drug Class central nervous system stimulants
    FDA Approval 1996
    Drug Class small molecule
    Drug Indications Central Nervous System Stimulants
    (4 More Sources)

    Publications:

    Mansvelder et al., 2009, Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits., Semin. Cell Dev. Biol.
    Zaniewska et al., Nicotine dependence - human and animal studies, current pharmacotherapies and future perspectives., Pharmacol Rep
    Mexal et al., 2007, alpha7 nicotinic receptor gene promoter polymorphisms in inbred mice affect expression in a cell type-specific fashion., J. Biol. Chem.
    Narahashi et al., 2000, Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior., Toxicol. Sci.
    Olincy et al., 2006, Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia., Arch. Gen. Psychiatry
    Jackson et al., 2010, Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice., J. Pharmacol. Exp. Ther.
    Rigbi A et al., 2011, Why do young women smoke? VI. A controlled study of nicotine effects on attention: pharmacogenetic interactions., Pharmacogenomics J
    Kuehl et al., 2003, N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases., Drug Metab. Dispos.
    Ehringer et al., 2007, Association of the neuronal nicotinic receptor beta2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine., Am. J. Med. Genet. B Neuropsychiatr. Genet.
    De Luca et al., 2006, Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia., Exp Brain Res
    Hoft NR et al., 2011, CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences., Genes Brain Behav
    Matera C et al., 2015, Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization., Eur J Med Chem
    Huang W et al., 2008, Significant association of DRD1 with nicotine dependence., Hum Genet
    Klaassen et al., 2006, Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy., Proc. Natl. Acad. Sci. U.S.A.
    Espeseth et al., 2007, Nicotine receptor gene CHRNA4 modulates early event-related potentials in auditory and visual oddball target detection tasks., Neuroscience
    Winterer et al., 2007, Association of attentional network function with exon 5 variations of the CHRNA4 gene., Hum. Mol. Genet.
    Gu F et al., 2020, Association Between Nicotine-dependent Gene Polymorphism and Smoking Cessation in Patients With Lung Cancer., Clin Lung Cancer
    Chu CJ et al., 2011, Association of nicotinic acetylcholine receptor subunit alpha-4 polymorphisms with smoking behaviors in Chinese male smokers., Chin Med J (Engl)
    Breitling LP et al., 2009, Association of nicotinic acetylcholine receptor subunit alpha 4 polymorphisms with nicotine dependence in 5500 Germans., Pharmacogenomics J
    Li MD et al., 2005, Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence., Hum Mol Genet
    Teitelbaum AM et al., 2018, Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain., Pharmacogenomics J
    Ghosheh et al., 2002, N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases., Drug Metab. Dispos.
    Mobascher A et al., 2010, Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2) with nicotine addiction., Am J Med Genet B Neuropsychiatr Genet
    Ichino et al., 2002, Increase of transcriptional levels of egr-1 and nur77 genes due to both nicotine treatment and withdrawal in pheochromocytoma cells., J Neural Transm (Vienna)
    Chen et al., 2002, Nicotine modulates the effects of retinoids on growth inhibition and RAR beta expression in lung cancer cells., Int. J. Cancer
    Bloom AJ et al., 2013, The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans., Pharmacogenet Genomics
    Chen G et al., 2008, Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines., Pharmacogenet Genomics
    Chen G et al., 2007, Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism., Cancer Res
    Choi HD et al., 2015, Association between catechol-O-methyltransferase (COMT) Val/Met genotype and smoking cessation treatment with nicotine: a meta-analysis., Pharmacogenomics
    Sun H et al., 2012, Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy., J Neural Transm (Vienna)
    Munafò MR et al., 2008, Association of COMT Val108/158Met genotype with smoking cessation., Pharmacogenet Genomics
    Beuten J et al., 2006, Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations., Neuropsychopharmacology
    David SP et al., 2002, No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation., Pharmacogenetics
    Ray R et al., 2007, Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial., Nicotine Tob Res
    Kumondai M et al., 2018, Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation., Drug Metab Pharmacokinet
    Shin-young et al., 2007, Nicotine inhibits bFGF-induced neurite outgrowth through suppression of NO synthesis in H19-7 cells., Neurochem. Res.
    Kaur-Knudsen D et al., 2014, CHRNA3 and CYP3A5*3 genotype, lung function and chronic obstructive pulmonary disease in the general population., Pharmacogenet Genomics
    Winterer G et al., 2010, Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance., Am J Med Genet B Neuropsychiatr Genet
    Audrain-McGovern et al., 2004, Interacting effects of genetic predisposition and depression on adolescent smoking progression., Am J Psychiatry
    Wuenschell et al., 2004, Nicotine-responsive genes in cultured embryonic mouse lung buds: interaction of nicotine and superoxide dismutase., Pharmacol. Res.
    Garcia KL et al., 2015, Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration., Neuropsychopharmacology
    Ring HZ et al., 2007, Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism., Pharmacogenet Genomics
    Johnstone E et al., 2006, Determinants of the rate of nicotine metabolism and effects on smoking behavior., Clin Pharmacol Ther
    Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Genbacev et al., Disruption of oxygen-regulated responses underlies pathological changes in the placentas of women who smoke or who are passively exposed to smoke during pregnancy., Reprod. Toxicol.
    Pandey et al., 2001, Effects of protracted nicotine exposure and withdrawal on the expression and phosphorylation of the CREB gene transcription factor in rat brain., J. Neurochem.
    Lee et al., 2005, Effects of nicotine on proliferation, cell cycle, and differentiation in immortalized and malignant oral keratinocytes., J. Oral Pathol. Med.
    Onoda et al., 2001, Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents., Head Neck
    Gold AB et al., 2012, Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation., Neuropsychopharmacology
    Lori A et al., 2011, The galanin receptor 1 gene associates with tobacco craving in smokers seeking cessation treatment., Neuropsychopharmacology
    Sullivan et al., 2004, Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics., Am. J. Med. Genet. B Neuropsychiatr. Genet.
    Stapleton JA et al., 2011, Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy., Pharmacogenet Genomics
    Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
    Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
    Türkan H et al., 2019, The association between the OPRM1 A118G polymorphism and addiction in a Turkish population., Arh Hig Rada Toksikol
    Chen YT et al., 2013, OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study., J Hum Genet
    Kleinjan M et al., 2013, Dual growth of adolescent smoking and drinking: evidence for an interaction between the mu-opioid receptor (OPRM1) A118G polymorphism and sex., Addict Biol
    Munafò MR et al., 2007, Association of the mu-opioid receptor gene with smoking cessation., Pharmacogenomics J
    Ray R et al., 2006, Association of OPRM1 A118G variant with the relative reinforcing value of nicotine., Psychopharmacology (Berl)
    Arias A et al., 2006, Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis., Drug Alcohol Depend
    Lerman C et al., 2004, The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial., Pharmacogenomics J
    Schinka JA et al., 2002, A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances., Mol Psychiatry
    Serres et al., 2006, Nicotine regulates SH-SY5Y neuroblastoma cell proliferation through the release of brain-derived neurotrophic factor., Brain Res.
    Bui et al., 1995, Comparative effects of 6-week nicotine treatment on blood pressure and components of the antioxidant system in male spontaneously hypertensive (SHR) and normotensive Wistar Kyoto (WKY) rats., Toxicology
    Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
    Cinciripini P et al., 2004, The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood., Nicotine Tob Res
    Wang et al., 2005, P-glycoprotein does not actively transport nicotine and cotinine., Addict Biol
    Tiili EM et al., 2015, Effect of genotype and methylation of CYP2D6 on smoking behaviour., Pharmacogenet Genomics
    Miller RT et al., 2014, Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys., Br J Pharmacol
    Yu Y et al., 2006, Intronic variants in the dopa decarboxylase (DDC) gene are associated with smoking behavior in European-Americans and African-Americans., Hum Mol Genet
    Lee et al., An in vitro bioassay for xenobiotics using the SXR-driven human CYP3A4/lacZ reporter gene., Int. J. Toxicol.
    Armstrong et al., 1996, Nicotine enhances expression of the neutrophil elastase gene and protein in a human myeloblast/promyelocyte cell line., Am. J. Respir. Crit. Care Med.
    Cucina et al., 1999, Nicotine regulates basic fibroblastic growth factor and transforming growth factor beta1 production in endothelial cells., Biochem. Biophys. Res. Commun.
    Zhong et al., 2008, Presynaptic type III neuregulin 1 is required for sustained enhancement of hippocampal transmission by nicotine and for axonal targeting of alpha7 nicotinic acetylcholine receptors., J. Neurosci.
    Dasgupta et al., 2006, Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin., Proc. Natl. Acad. Sci. U.S.A.
    Ma JZ et al., 2010, Significant association of glutamate receptor, ionotropic N-methyl-D-aspartate 3A (GRIN3A), with nicotine dependence in European- and African-American smokers., Hum Genet
    Greiff et al., 1991, [Significant effects on alpha-fetoprotein (AFP) concentration in maternal serum in pregnancy]., Zentralbl Gynakol
    Frazer-Abel et al., 2004, Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells., J. Pharmacol. Exp. Ther.
  • NICOTINE   CHRNA9

    Interaction Score: 3.86

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11006350 19560048 20400469 20081230


    Sources:
    TdgClinicalTrial TEND

  • NICOTINE   HINT1

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17978999


    Sources:
    PharmGKB

  • NICOTINE   UGT2B10

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24192532 18300939 17909004


    Sources:
    PharmGKB

  • NICOTINE   CHRNA10

    Interaction Score: 1.93

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11006350 19560048 20400469 20081230


    Sources:
    TdgClinicalTrial TEND

  • NICOTINE   GALR1

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22373943 21430647


    Sources:
    PharmGKB

  • NICOTINE   CYP2A13

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29342418


    Sources:
    PharmGKB

  • NICOTINE   CHRNB2

    Interaction Score: 1.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Neuronal acetylcholine receptor; alpha4/beta2 agonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    17226798 19560048 20081230 11006350 16636791 20400469 20854418 26164842


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • NICOTINE   CHRNA4

    Interaction Score: 0.71

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Neuronal acetylcholine receptor; alpha4/beta2 agonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    17146052 17226798 19560048 20081230 17590520 17613539 11006350 16636791 20400469 31402126 21740768 20854418 19290018 15790597 26164842


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • NICOTINE   DDC

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16740595


    Sources:
    PharmGKB

  • NICOTINE   EPB41

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NICOTINE   ADGRL3

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NICOTINE   CREB1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11331423


    Sources:
    NCI

  • NICOTINE   CHRNA3

    Interaction Score: 0.64

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    11006350 19560048 20400469 20081230 31402126 24535486 20886544


    Sources:
    PharmGKB

  • NICOTINE   CHRNB4

    Interaction Score: 0.59

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    20886544 11006350 19560048 20400469 20081230


    Sources:
    PharmGKB

  • NICOTINE   CHRNA2

    Interaction Score: 0.5

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    15048644 11006350 19560048 20400469 20081230


    Sources:
    TdgClinicalTrial TEND

  • NICOTINE   FMO1

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NICOTINE   ANKK1

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21540761 19273465 15077009


    Sources:
    PharmGKB

  • NICOTINE   NR4A1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12111438 11979430


    Sources:
    NCI

  • NICOTINE   CHRNA7

    Interaction Score: 0.35

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    19560048 20081230 17360707 11006350 16754836 20400469 20231857


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • NICOTINE   ELANE

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8912774


    Sources:
    NCI

  • NICOTINE   FMO3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28290528


    Sources:
    PharmGKB

  • NICOTINE   UGT1A7

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12167564


    Sources:
    NCI

  • NICOTINE   COMT

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26555332 22695756 18192898 16395295 11927842


    Sources:
    PharmGKB

  • NICOTINE   AFP

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1711749


    Sources:
    NCI

  • NICOTINE   CP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7740554


    Sources:
    NCI

  • NICOTINE   UGT1A4

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14570768


    Sources:
    NCI

  • NICOTINE   VHL

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14555188


    Sources:
    NCI

  • NICOTINE   POR

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NICOTINE   E2F1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16601104


    Sources:
    NCI

  • NICOTINE   CYP2B6

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25652250 18004205 17015050 11470993 17638512


    Sources:
    PharmGKB

  • NICOTINE   NTF3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17268847


    Sources:
    NCI

  • NICOTINE   CDKN1A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16011614


    Sources:
    NCI

  • NICOTINE   OPRM1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31246565 23223006 22260295 17224915 16960700 16387451 15007373 11840318


    Sources:
    PharmGKB

  • NICOTINE   NRG1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18784291


    Sources:
    NCI

  • NICOTINE   HTR3B

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NICOTINE   DDIT3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11592233


    Sources:
    NCI

  • NICOTINE   CDK4

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15231866


    Sources:
    NCI

  • NICOTINE   GRIN3A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20084518


    Sources:
    PharmGKB

  • NICOTINE   TGFB1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10198208


    Sources:
    NCI

  • NICOTINE   BAX

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15225679


    Sources:
    NCI

  • NICOTINE   SLC6A3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15229055


    Sources:
    NCI

  • NICOTINE   CHRM2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19644963


    Sources:
    PharmGKB

  • NICOTINE   BDNF

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16790237


    Sources:
    NCI

  • NICOTINE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16123753 15203796


    Sources:
    PharmGKB

  • NICOTINE   DRD1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18092181


    Sources:
    PharmGKB

  • NICOTINE   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16191663


    Sources:
    NCI

  • NICOTINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26287939 24611668


    Sources:
    PharmGKB

  • NICOTINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12851153


    Sources:
    NCI

  • TEND: NICOTINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class central nervous system stimulants
    Year of Approval 1996

    Publications:

  • TdgClinicalTrial: NICOTINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Central Nervous System Stimulants
    Drug Class small molecule
    FDA Approval 1996

    Publications:

  • NCI: NICOTINE

    • Version: 14-September-2017

    Alternate Names:
    C691 NCI drug code

    Drug Info:

    Publications:
    Ghosheh et al., 2002, N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases., Drug Metab. Dispos.
    Ichino et al., 2002, Increase of transcriptional levels of egr-1 and nur77 genes due to both nicotine treatment and withdrawal in pheochromocytoma cells., J Neural Transm (Vienna)
    Chen et al., 2002, Nicotine modulates the effects of retinoids on growth inhibition and RAR beta expression in lung cancer cells., Int. J. Cancer

  • DTC: NICOTINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL3 ChEMBL Drug ID

    Drug Info:

    Publications:
    Matera C et al., 2015, Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization., Eur J Med Chem

  • PharmGKB: nicotine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Huang W et al., 2008, Significant association of DRD1 with nicotine dependence., Hum Genet
    Teitelbaum AM et al., 2018, Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain., Pharmacogenomics J
    Mobascher A et al., 2010, Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2) with nicotine addiction., Am J Med Genet B Neuropsychiatr Genet

  • TTD: Nicotine

    • Version: 2020.06.01

    Alternate Names:
    D0T8GD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21